Stockreport

Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence [Yahoo! Finance]

Fate Therapeutics, Inc.  (FATE) 
Last fate therapeutics, inc. earnings: 3/2 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.fatetherapeutics.com/investor-relations
PDF Initial Phase 1 Clinical Data in Relapsed / Refractory B-cell Lymphoma Show Favorable Safety Profile, Complete Responses, and Persistence of FT522 Live Cells Selectiv [Read more]